Kamada (KMDA) Net Cash Flow (2012 - 2026)
Kamada's (KMDA) quarterly Net Cash Flow came in at -$3.5 million in Q2 2026, up 65.68% on a YoY basis from -$2.1 million in Q2 2025, and up 91.81% quarter-over-quarter from -$42.3 million in Q1 2026.
Analysis
Kamada (KMDA) Net Cash Flow (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported Net Cash Flow for 15 consecutive years, with -$3.5 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Net Cash Flow rose 65.68% year-over-year to -$3.5 million; the trailing twelve-month figure through Jun 2026 stood at -$36.1 million (down 472.82% YoY), and the FY2025 full-year result was -$2.7 million, down 111.74% from the prior year.
- Net Cash Flow climbed to -$3.5 million in Q2 2026 per KMDA's latest filing, from -$42.3 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $30.5 million in Q3 2023 and bottomed at -$42.3 million in Q1 2026.
- Historically, Net Cash Flow has averaged $612666.7 across 5 years, with a median of $2.7 million in 2022.
- The sharpest annual moves came in 2023 and 2026: Net Cash Flow soared 1787.74% in 2023, then tumbled 1768.71% in 2026.
- Over 5 years, Net Cash Flow stood at $2.9 million in 2022, then declined by 11.68% to $2.6 million in 2023, then soared by 164.71% to $6.8 million in 2024, then sank by 46.62% to $3.6 million in 2025, then tumbled by 196.07% to -$3.5 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$3.5 million, -$42.3 million, and $3.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 1.95 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -4.43 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 652.90 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | -504.30 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -183.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | -496,000.00 |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | -2.09 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -170.75 Mn |
| 10 | Kamada | 473.57 Mn | 403.43 Mn | 22.47 Mn | -3.47 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -3.47 Mn |
| Mar 31, 2026 | -42.35 Mn |
| Dec 31, 2025 | 3.61 Mn |
| Sep 30, 2025 | 6.07 Mn |
| Jun 30, 2025 | -10.11 Mn |
| Mar 31, 2025 | -2.27 Mn |
| Dec 31, 2024 | 6.77 Mn |
| Sep 30, 2024 | 15.30 Mn |
| Jun 30, 2024 | 8.28 Mn |
| Mar 31, 2024 | -7.40 Mn |
| Dec 31, 2023 | 2.56 Mn |
| Sep 30, 2023 | 30.49 Mn |
| Jun 30, 2023 | -5.09 Mn |
| Mar 31, 2023 | -6.83 Mn |
| Dec 31, 2022 | 2.89 Mn |
| Sep 30, 2022 | 1.62 Mn |
| Jun 30, 2022 | 7.81 Mn |
| Mar 31, 2022 | 3.14 Mn |
| Dec 31, 2021 | -81.01 Mn |
| Sep 30, 2021 | 31.60 Mn |